Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$129.25 USD
+5.00 (4.02%)
Updated Apr 25, 2024 12:06 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
SRPT 129.25 +5.00(4.02%)
Will SRPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
Other News for SRPT
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Edgewise gets EU orphan drug status for muscular dystrophy drug
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
As more rare disease therapies launch, their prices are rising
Noteworthy Thursday Option Activity: SRPT, GFF, ADBE